

**RULE 1.3/1.4 - PROFORMA APPLICATION ANNOUNCEMENT**

<i>Please submit the form by email in an MS Word document to <a href="mailto:aqse regulation@quis.eu">aqse regulation@quis.eu</a>.</i> <b>ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQSE GROWTH MARKET</b>
<b>APPLICANT NAME:</b>
<b>PROBIOTIX HEALTH PLC</b>
<b>APPLICANT REGISTERED OFFICE, PRINCIPAL PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:</b>
Cavalier Suite The Barracks Wakefield Road Pontefract WF8 4HH  Tel: 020 7933 8786 (via Walbrook pr)
<b>DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):</b>
Adam Reynolds (Non-executive Chairman) Stephen O'Hara (Chief Executive Officer) Mikkel Hvid-Hansen (Commercial Director) Marco Caspani (Non-executive Director)
<b>APPLICANT SECTOR:</b>
Pharmaceuticals and Biotechnology
<b>DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:</b>
ProBiotix develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome, and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world.  ProBiotix's cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 ("LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.
<b>NAME OF AQSE CORPORATE ADVISER:</b>
Peterhouse Capital Limited
<b>NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:</b>
TBC; Ordinary Shares of 0.05p each
<b>SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):</b>
TBC

**SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT'S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:**

Shareholder	Current Ordinary Shares	%	Ordinary Shares on Admission	% on Admission
OptiBiotix Health plc	100,000,000	100	TBC	TBC
Global Prime Partners Ltd*	-	-	TBC	TBC

\*As nominee recipient of the Ordinary Shares to be transferred by OptiBiotix Health plc to its shareholders

**TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:**

N/A

**THE EXPECTED ADMISSION DATE:**

Thursday, 31 March 2022

**WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:**

[www.probiotixhealth.com](http://www.probiotixhealth.com)

*In respect of a fast-track applicant, the following information should also be included:*

**NAME OF MARKET ON WHICH THE APPLICANT'S SECURITIES ARE CURRENTLY TRADED:****ARRANGEMENTS FOR THE SETTLEMENT OF TRANSACTIONS IN THE APPLICANT'S SECURITIES:****DETAILS OF ANY LOCK-IN ARRANGEMENTS:****DETAILS OF THE LEGAL OR REGULATORY REQUIREMENTS IN THE APPLICANT'S HOME COUNTRY REGARDING THE CONDUCT OF TAKEOVERS AND THE ACQUISITION OF SIGNIFICANT VOTING RIGHTS TO WHICH THE APPLICANT IS SUBJECT:**

*In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:*

**UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:**